Cathie Wood Dumps Tech Stocks for Gene-Editing Plays in CRISPR and Beam

TLDR Cathie Wood’s ARK Invest purchased $10.06 million worth of CRISPR Therapeutics shares and $7.06 million in Beam Therapeutics stock on November 4, 2025. ARK reduced technology holdings by selling $5.02 million in Teradyne shares and $1.67 million in Roku stock through its ARKK fund. The firm sold $627,455 worth of SoFi Technologies shares through [...]

The post Cathie Wood Dumps Tech Stocks for Gene-Editing Plays in CRISPR and Beam appeared first on Blockonomi.